Forte Biosciences (FBRX) Interest Expenses (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Interest Expenses of $43.7 million for Q1 2026, up 5211.44% year-over-year from $822000.0 in Q1 2025, and up 101434.88% quarter-over-quarter from $43000.0 in Q4 2025.
Forte Biosciences (FBRX) Interest Expenses (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Interest Expenses for 11 consecutive years, with $43.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 5211.44% year-over-year to $43.7 million; the TTM figure through Mar 2026 stood at $43.7 million (up 5211.44% YoY), while the FY2025 annual figure was $47.1 million, up 92.12% from the prior year.
- Interest Expenses advanced to $43.7 million in Q1 2026 per FBRX's latest filing, from $43000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $43.7 million in Q1 2026 and bottomed at $5000.0 in Q3 2023.
- Historically, Interest Expenses has averaged $4.5 million across 5 years, with a median of $81000.0 in 2024.
- Annual changes were most pronounced in 2022 — Interest Expenses sank 99.06% — and 2025, when it soared 62082.14%.
- Forte Biosciences' Interest Expenses stood at $65000.0 in 2022, then tumbled by 53.85% to $30000.0 in 2023, then surged by 170.0% to $81000.0 in 2024, then tumbled by 46.91% to $43000.0 in 2025, then soared by 101434.88% to $43.7 million in 2026.
- Business Quant data shows FBRX's Interest Expenses at $43.7 million in Q1 2026, $43000.0 in Q4 2025, and $17.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 34.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.34 Mn |
| Jun 30, 2026 | 34.34 Mn |
| Mar 31, 2026 | 43.66 Mn |
| Mar 31, 2026 | 43.66 Mn |
| Dec 31, 2025 | 43,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | 17.41 Mn |
| Sep 30, 2025 | 17.41 Mn |
| Jun 30, 2025 | 13.03 Mn |
| Jun 30, 2025 | 13.03 Mn |
| Mar 31, 2025 | 822,000.00 |
| Mar 31, 2025 | 822,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Mar 31, 2024 | 28,000.00 |